Folinic Acid as a Treatment for Autism Spectrum Disorder in Children (FOLIN-A)
Folinic Acid as a Treatment for Autism Spectrum Disorder in Children: A Double-blind Randomised Placebo-controlled Trial With Open Label Extension (FOLIN-A Trial)
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 2
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Study Coordinator
- Numero di telefono: 6563947201
- Email: folin-a@kkh.com.sg
Luoghi di studio
-
-
Singapore
-
Singapore, Singapore, Singapore
- Reclutamento
- KK Women's and Children's Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
- Bambino
Accetta volontari sani
Descrizione
Inclusion Criteria:
- Children aged 3 years 0 months to 10 years 11 months at the time of enrolment
- Weight ≥ 10 kg and ≤ 30 kg at the time of enrolment
- Confirmed diagnosis of Autism Spectrum Disorder (ASD) based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) or Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria, supported by standardized diagnostic assessments
- Stable on regular behavioral interventions and any medications for at least 6 months prior to enrolment
- At least one parent or legal guardian able to understand and complete study questionnaires in English
- Written informed consent obtained from a parent or legal guardian
Exclusion Criteria:
- Known allergy or intolerance to folinic acid
- Current or prior supplementation with folinic acid or other folate preparations (folic acid supplementation permitted)
- Vitamin B12 (cobalamin) deficiency or pernicious anemia
- Concurrent use of medications known to interfere with folate metabolism (e.g., methotrexate, trimethoprim, fluorouracil, capecitabine, glucarpidase)
- Known genetic, metabolic, or chromosomal disorder, or structural brain abnormalities
- History of epilepsy or seizures (except simple febrile seizures) or current use of antiepileptic or antipsychotic medication
- Significant sensory (hearing or visual) or motor impairment
- Participation in another interventional clinical trial for autism within the past 6 months
- Unable or unwilling to comply with study visits and procedures
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Folinic Acid
Participants in this arm will receive folinic acid during the double-blind randomised controlled trial (RCT) phase of the study.
After completion of the double-blind phase, participants will continue into an open-label extension in which folinic acid is provided.
|
Oral folinic acid administered during the double-blind randomised controlled trial (RCT) phase, followed by open-label folinic acid treatment.
|
|
Comparatore placebo: Placebo
Participants in this arm will receive a matching placebo during the double-blind randomised controlled trial (RCT) phase of the study.
After completion of the double-blind phase, participants will continue into an open-label extension in which folinic acid is provided.
|
Matching oral placebo administered during the double-blind randomised controlled trial (RCT) phase.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in Pervasive Developmental Disorder-Behavior Inventory (PDDBI) Autism Composite T-Score
Lasso di tempo: Baseline to Week 12
|
The Pervasive Developmental Disorder-Behavior Inventory (PDDBI) is a validated caregiver-completed instrument used to assess adaptive and maladaptive behaviors in individuals with autism spectrum disorder (ASD).
The Autism Composite T-score is a standardized score (mean = 50, standard deviation = 10) that summarizes overall autism symptom severity, with higher scores indicating greater symptom severity.
This outcome measure evaluates the change from baseline to Week 12 in PDDBI Autism Composite T-score.
Lower T-scores indicate improvement in autism-related symptoms.
Changes in scores will be compared between participants receiving folinic acid and those receiving placebo.
|
Baseline to Week 12
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change from baseline in language function as measured by the Clinical Evaluation of Language Fundamentals (CELF)
Lasso di tempo: Baseline to Week 12
|
Change from baseline to Week 12 in standardized language function scores as assessed using the Clinical Evaluation of Language Fundamentals (CELF), a standardized individually administered assessment of receptive and expressive language skills in children.
CELF standardized scores have a mean of 100 and a standard deviation of 15, with higher scores indicating better language performance.
Changes in scores will be compared between participants receiving folinic acid and those receiving placebo.
|
Baseline to Week 12
|
|
Change from baseline in receptive vocabulary score as measured by the Receptive One-Word Picture Vocabulary Test (ROWPVT)
Lasso di tempo: Baseline to Week 12
|
Change from baseline to Week 12 in standardized receptive vocabulary scores as assessed using the Receptive One-Word Picture Vocabulary Test (ROWPVT), a standardized individually administered assessment of a child's ability to understand spoken words.
Scores are standardized with a mean of 100 and a standard deviation of 15, where higher scores indicate better receptive vocabulary ability.
Changes in scores will be compared between participants receiving folinic acid and those receiving placebo.
|
Baseline to Week 12
|
|
Change from baseline in expressive vocabulary score as measured by the Expressive One-Word Picture Vocabulary Test (EOWPVT)
Lasso di tempo: Baseline to Week 12
|
Change from baseline to Week 12 in standardized expressive vocabulary scores as assessed using the Expressive One-Word Picture Vocabulary Test (EOWPVT), a standardized individually administered assessment of a child's ability to produce spoken words.
Scores are standardized with a mean of 100 and a standard deviation of 15, where higher scores indicate better expressive vocabulary ability.
Changes in scores will be compared between participants receiving folinic acid and those receiving placebo.
|
Baseline to Week 12
|
|
Change from baseline in Clinical Global Impression-Severity and Improvement scores as measured by the Clinical Global Impression Scale (CGI-S and CGI-I)
Lasso di tempo: Baseline to Week 12
|
Change from baseline to Week 12 in Clinical Global Impression-Severity (CGI-S) and Clinical Global Impression-Improvement (CGI-I) scores, assessed using the Clinical Global Impression Scale, a standardized assessor-rated measure of illness severity and overall clinical improvement.
CGI-S scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill), where lower scores indicate better outcomes, and CGI-I scores range from 1 (very much improved) to 7 (very much worse), where lower scores indicate greater improvement.
Changes in scores will be compared between participants receiving folinic acid and those receiving placebo.
|
Baseline to Week 12
|
|
Change from baseline in Aberrant Behavior Checklist total score as measured by the Aberrant Behavior Checklist (ABC)
Lasso di tempo: Baseline to Week 12
|
Change from baseline to Week 12 in total scores on the Aberrant Behavior Checklist (ABC), a standardized caregiver-completed questionnaire that assesses behavioural symptoms in children across domains such as irritability, lethargy, stereotypy, hyperactivity, and inappropriate speech.
Total scores range from 0 to 174, with higher scores indicating greater severity of behavioural problems (worse outcomes).
Changes in scores will be compared between participants receiving folinic acid and those receiving placebo.
|
Baseline to Week 12
|
|
Change from baseline in total problem score as measured by the Child Behavior Checklist (CBCL)
Lasso di tempo: Baseline to Week 12
|
Change from baseline to Week 12 in total problem scores on the Child Behavior Checklist (CBCL), a standardized caregiver-reported questionnaire that assesses a broad range of emotional and behavioural problems in children.
Total scores are standardised T-scores (typically ranging from approximately 30 to 100, with a mean of 50 and standard deviation of 10), where higher scores indicate greater behavioural and emotional problems (worse outcomes).
Changes in scores will be compared between participants receiving folinic acid and those receiving placebo.
|
Baseline to Week 12
|
|
Change from baseline in adaptive behavior composite score as measured by the Vineland Adaptive Behavior Scales (VABS)
Lasso di tempo: Baseline to Week 12
|
Change from baseline to Week 12 in standardised adaptive behavior scores as assessed using the Vineland Adaptive Behavior Scales (VABS), a standardized caregiver-reported assessment of a child's adaptive functioning across domains such as communication, daily living skills, socialization, and motor skills.
Adaptive behavior composite scores are standardised (typically ranging from approximately 20 to 160, with a mean of 100 and standard deviation of 15), where higher scores indicate better adaptive functioning (better outcomes).
Changes in scores will be compared between participants receiving folinic acid and those receiving placebo.
|
Baseline to Week 12
|
|
Change from baseline in proportion of gaze duration to social stimuli as measured by eye-tracking assessment
Lasso di tempo: Baseline to Week 12
|
Change from baseline to Week 12 in eye-tracking measures of visual attention, specifically the proportion of total gaze duration directed toward social stimuli (e.g., faces or biological motion) compared with non-social stimuli, assessed using a standardized eye-tracking paradigm.
Higher proportions indicate greater relative attention to social stimuli.
Changes in proportions will be compared between participants receiving folinic acid and those receiving placebo.
|
Baseline to Week 12
|
|
Incidence of adverse events and serious adverse events as measures of safety and tolerability of folinic acid
Lasso di tempo: Baseline to Week 24
|
Change from baseline to Week 24 in the incidence of adverse events (AEs) and serious adverse events (SAEs), monitored throughout the study period to assess the safety and tolerability of folinic acid treatment.
|
Baseline to Week 24
|
Altre misure di risultato
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change from baseline in plasma glutathione redox ratio (GSH:GSSG)
Lasso di tempo: Baseline to Week 12
|
Change from baseline to Week 12 in plasma glutathione redox ratio (reduced glutathione:oxidized glutathione; GSH:GSSG), a biomarker of oxidative stress balance.
Higher ratios indicate a more reduced (favorable) redox state.
Plasma reduced glutathione (GSH, µM) and oxidized glutathione (GSSG, µM) will be measured at baseline (T1) and Week 12 (T2).
|
Baseline to Week 12
|
|
Change from baseline in plasma methylation ratio (S-adenosylmethionine:S-adenosylhomocysteine; SAM:SAH)
Lasso di tempo: Baseline to Week 12
|
Change from baseline to Week 12 in plasma methylation ratio (S-adenosylmethionine:S-adenosylhomocysteine; SAM:SAH), a biomarker of methylation capacity.
Higher ratios indicate greater methylation potential (better outcomes).
Additional biomarkers related to one-carbon metabolism, including plasma homocysteine (µmol/L), will measured where available.
|
Baseline to Week 12
|
|
Change in Plasma Ergothioneine Levels
Lasso di tempo: Baseline to Week 12
|
Change from baseline to Week 12 in plasma ergothioneine concentration (ET, nM).
Plasma ergothioneine (ET, nM), hercynine (nM), and ophthalmic acid will be measured at baseline (T1) and Week 12 (T2).
|
Baseline to Week 12
|
|
Change in Folate Status Biomarkers
Lasso di tempo: Baseline to Week 12
|
Change from baseline in serum and plasma folate status biomarkers.
Folate status biomarkers include measures related to one-carbon metabolism and amino acid pathways.
Plasma amino acid concentrations (µmol/L) will be interpreted with reference to established age-specific clinical ranges.
|
Baseline to Week 12
|
|
Association of FRAA Status With Treatment Response
Lasso di tempo: Baseline to Week 12
|
Association between folate receptor autoantibody (FRAA) status and change in autism outcome measures.
FRAA status will be classified as positive or negative based on the assay-specific cutoff defined by the testing laboratory: Blocking FRAA (pmol blocked per mL) and binding FRAA (optical density [OD] units per µL).
|
Baseline to Week 12
|
|
Sustained Effects of Folinic Acid on Autism Symptoms
Lasso di tempo: Baseline to Week 24
|
Change from baseline in autism outcome measures following 24 weeks of folinic acid treatment.
|
Baseline to Week 24
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Disordini mentali
- Disturbi del neurosviluppo
- Disturbi dello sviluppo infantile, pervasivi
- Disturbo dello spettro autistico
- Composti eterociclici
- Composti eterociclici, 2 anelli
- Composti eterociclici, anello fuso
- Enzimi e coenzimi
- Formyltetraidrofolates
- Tetraidrofolati
- Acido folico
- Pterins
- Pteridine
- Coenzimi
- Leucovorina
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- FOLIN-A-01
- MOH-CIRG24jan-0004 (Altro numero di sovvenzione/finanziamento: National Medical Research Council (NMRC), Singapore)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .